Efficacy and safety of ambroxol for bronchiolitis: A systematic review
- Author:
Na SU
1
Author Information
1. Department of Pharmacy
- Publication Type:Journal Article
- Keywords:
Ambroxol;
Bronchiofitis;
Meta-analysis
- From:
Chinese Pharmaceutical Journal
2012;47(14):1158-1163
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To review the efficacy and safety of ambroxol for treatment of bronchiofitis. METHODS: Random controlled trials (RCTs), systematic review (SR), and meta-analysis of ambroxol for treatment of bronchiofitis were searched in Cochrane, PubMed, Embase, ISI, CBMdisc, CNKI, VIP and Wangfang database; the methodology quality of every RCT was evaluated, then meta-analysis was performed by software of RevMan5.0.0. RESULTS: Twenty-nine RCTs were included. According to the meta-analysis results, the effective rate in ambroxol group was better than the control group [RR 1.25,95% CI (1.20, 1.30), P < 0.00001]. The time of hospital stay was obviously shorter than the control group [RR-1.38,95% CI(-1.67, -1.08), P < 0.00001]. The recovery of respiratory system symptoms in ambroxol group was earlier than that in the control group (P < 0.01). ADR had no significant difference between the ambroxol and control groups. CONCLUSION: Ambroxol can improve the respiratory system symptoms of bronchiofitis and reduce the time of hospital stay. Ambroxol has remarkable and predictable effect. Copyright 2012 by the Chinese Pharmaceutical Association.
